IDYA Similar Chart Price Prediction
The price of IDYA is predicted to go up -6.91%, based on the high correlation periods with AR. The similarity of these two price pattern on the periods is 97.13%.
IDYA
AR
Down: -6.91%Similarity: 97.13%
IDYA Revenue Forecast
IDYA EPS Forecast
IDYA FAQs
What is IDYA revenue forecast for next quarter？
What is IDYA eps forecast for next quarter？
IDYA Analyst's Forecast
Sudan Loganathan
Stephens & Co.
Buy
2024-11-18
Price Target
$51
Upside
+94.73%
Stephens initiated coverage of Ideaya Biosciences with an Overweight rating and $51 price target. The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation, or TPD, technology and commercial and clinical-stage rare disease-focused companies. Ideaya's lead asset is in Phase 2/3 potential registrational trials for the treatment of metastatic uveal melanoma, or MUM, and it has a "robust pipeline" in development for multiple solid tumor indications, the analyst tells investors.
Christopher Liu
Leerink Partners
Buy → Hold
2024-11-05
Price Target
$41 → $27
Downside
-8.72%
David Dai
UBS
Strong Buy
2024-10-24
Price Target
$50
Upside
+71.23%
